David Hirsch

David Hirsch is a founder and Managing Director of Longitude Capital. He focuses on investments in biotechnology. From 2005 to 2006, David Hirsch was a Vice President of Pequot Ventures where he worked in the life sciences practice. Prior to Pequot, David Hirsch was an Engagement Manager in the pharmaceutical practice of McKinsey & Company. While at McKinsey, he worked with many large pharmaceutical companies across a range of projects including clinical and commercial strategies, M&A evaluations, portfolio prioritization and managed care strategy. He currently serves on the boards of Civitas Therapeutics and Precision Therapeutics and is a board observer at InfaCare Pharmaceuticals and Xanodyne Pharmaceuticals. He is also actively involved with Longitude’s investments in Amarin (NASDAQ: AMRN) and Corcept Therapeutics (NASDAQ: CORT), as well as prior investments in Horizon Therapeutics and Sequenom (NASDAQ: SQNM).